logo
4,000-year-old victim was shot in the back—and survived with an arrow to the rib

4,000-year-old victim was shot in the back—and survived with an arrow to the rib

A flint arrowhead lodged in a rib from a person who lived in the Spanish Pyrenees more than 4,000 years ago was most likely shot during a skirmish with a rival clan, researchers say.
"It is direct evidence of a violent conflict episode," says Carlos Tornero, who led the team that unearthed the rib in a mountain cave 6,000 feet above sea level near the Spanish-French border. His team announced the finding July 8.
Previous excavations at the cave—called Roc de les Orenetes, or "Rock of the Swallows" in Catalan—unearthed thousands of human bones. Some had fractures and cut marks apparently caused by stone-tipped spears, arrows, and copper or bronze axes and daggers. The researchers published their analysis of the bones last year and concluded the injuries came from conflicts with other groups. This latest finding reinforces that idea. The interior of the cave as seen from the entrance. Photograph by Leo Pérez, IPHES-CERCA
"This extraordinary discovery is direct proof, and confirms our initial hypothesis," says Tornero, an archaeologist at the Autonomous University of Barcelona (UAB) and a researcher at the Catalan Institute of Human Paleoecology and Social Evolution (IPHES-CERCA).
Little is known about who shot the arrow, except that they were probably from an enemy group who fought violently against the people later buried in the cave—in a dispute over territory, or perhaps access to resources. The researchers dated the violent episodes to between 2550 and 2150 B.C.
Tornero says the victims in the cave were likely from a single clan of Early Bronze Age farming people; but their attackers may have been nomadic hunters. The archer shot this individual from behind so the arrow lodged in their back, within the rib cage but below the shoulder blade.
"Undoubtedly, the person who was struck had little ability to react in time to avoid it," says Tornero. Excavation work at the Roc de les Orenetes site, where human remains dating to 2400 BC can be seen in the foreground. Photograph by Leo Pérez, IPHES-CERCA The moment of the discovery of a flint arrowhead with a broken tip, dated to 2400 BC. Photograph by Iván Ramírez, IPHES-CERCA
Each arrowhead found in the cave was likely once embedded in the flesh of the dead people interred there, he says. But this individual did not die from their arrow wound—instead, the rib bone shows signs of healing that indicate the victim lived for a long time after their close encounter with death, Tornero says.
Roc de les Orenetes was discovered in 1969, and the remains of 60 bodies—many bearing scars from battle—have since been unearthed there, although only one-third of the site has been excavated, according to Tornero. The newly found arrowhead is another indicator of the violent conflicts in prehistory, as well as final proof for Tornero that the ancient people buried at Roc de les Orenetes were sometimes the victims of violence—and may have been the perpetrators of deadly violence in return.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy

Yahoo

time17 hours ago

  • Yahoo

Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy

Phase 3 trial clearance is based on the Phase 1/2 results demonstrating safety and efficacy of the 3x10¹³ vg/kg dose of microdystrophin, which is lower than doses used in other gene therapies for Duchenne muscular dystrophy (DMD). The double blind trial will be initiated in the UK and France beginning in August and September, and will enroll 64 boys aged 6 to 10 with DMD who have retained their walking ability. PARIS, July 28, 2025--(BUSINESS WIRE)--Genethon, a worldwide pioneer and leader in research and development in gene therapy for rare genetic diseases, has received approvals from regulatory authorities, MHRA and EMA*, to begin pivotal Phase 3 clinical trials in France and the UK of its gene therapy, GNT0004, for Duchenne muscular dystrophy (DMD). Genethon CEO Frederic Revah observed, "We are delighted to be able to continue these trials and are determined to bring GNT0004 to market for young patients and their families who are waiting for a therapeutic solution. This marks a decisive step forward for our gene therapy program for DMD, which began in 2021 and has demonstrated extremely promising results in the first children treated in the Phase1/2 portion of our Phase1/2/3 study." Dr. Revah added, "In addition to the very positive results in patients treated in the early phases, one of the strengths of our product is the dose selected for the pivotal phase, which is lower than those used in other gene therapy trials for DMD. Approvals of our Phase 3 trials reflect the regulatory authorities' confidence in GNT0004 as well as the work accomplished by our teams." The Phase 3 authorizations in Europe are based on the results of Phase 1/2 studies showing good tolerance of GNT0004 as well as efficacy in terms of microdystrophin expression, creatine phosphokinase (CPK) reduction, and motor function. Patients showed prolonged improvement or stabilization of motor functions and significant persistent reduction in CPK, a key marker of muscle damage. The Phase 3 double blind trials will begin in August and September in the UK and France using a single intravenous injection of GNT0004, which contains an optimized hMD1 transgene, a shortened (3x10¹³ vg/kg microdystrophin) but functional version of the gene encoding dystrophin in an AAV8 vector associated with transient immunological prophylactic treatment. The vector is designed to express itself in muscle tissue and the heart thanks to a Spc5-12 promoter sequence specific to these tissues. A total of 64 boys aged 6 to 10 with DMD who have retained their walking ability will be enrolled. * French ANSM as reporting member state for the EMA About Duchenne muscular dystrophy Duchenne muscular dystrophy is a rare progressive genetic disease that affects all the muscles in the body and mainly boys (1 in 5,000). It is caused by abnormalities in the gene responsible for the production of dystrophin, a structural protein essential for the stability of muscle fiber membranes and their metabolism. The absence of dystrophin leads to progressive degeneration of the skeletal and cardiac muscles, loss of walking and respiratory capacity, progressive heart failure, and death between the ages of 20 and 40. About Genethon A pioneer in the discovery and development of gene therapies for rare diseases, Genethon is a non-profit laboratory created by the AFM-Telethon. A first gene therapy drug, to which Genethon contributed, has been approved for marketing for spinal muscular atrophy. With more than 240 scientists and experts, Genethon's goal is to develop innovative therapies that change the lives of patients suffering from rare genetic diseases. Thirteen gene therapy products developed by Genethon or to which Genethon has contributed are currently undergoing clinical trials for diseases of the liver, blood, immune system, muscles, and eyes. Seven other products are in preparation for clinical trials over the next five years. View source version on Contacts Press contact:Marion Delbouis/Stéphanie Bardon – communication@ / +33 (0)6 45 15 95 87 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy

Business Wire

time19 hours ago

  • Business Wire

Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy

PARIS--(BUSINESS WIRE)--Genethon, a worldwide pioneer and leader in research and development in gene therapy for rare genetic diseases, has received approvals from regulatory authorities, MHRA and EMA*, to begin pivotal Phase 3 clinical trials in France and the UK of its gene therapy, GNT0004, for Duchenne muscular dystrophy (DMD). Genethon CEO Frederic Revah observed, 'We are delighted to be able to continue these trials and are determined to bring GNT0004 to market for young patients and their families who are waiting for a therapeutic solution. This marks a decisive step forward for our gene therapy program for DMD, which began in 2021 and has demonstrated extremely promising results in the first children treated in the Phase1/2 portion of our Phase1/2/3 study.' Dr. Revah added, 'In addition to the very positive results in patients treated in the early phases, one of the strengths of our product is the dose selected for the pivotal phase, which is lower than those used in other gene therapy trials for DMD. Approvals of our Phase 3 trials reflect the regulatory authorities' confidence in GNT0004 as well as the work accomplished by our teams.' The Phase 3 authorizations in Europe are based on the results of Phase 1/2 studies showing good tolerance of GNT0004 as well as efficacy in terms of microdystrophin expression, creatine phosphokinase (CPK) reduction, and motor function. Patients showed prolonged improvement or stabilization of motor functions and significant persistent reduction in CPK, a key marker of muscle damage. The Phase 3 double blind trials will begin in August and September in the UK and France using a single intravenous injection of GNT0004, which contains an optimized hMD1 transgene, a shortened (3x10¹³ vg/kg microdystrophin) but functional version of the gene encoding dystrophin in an AAV8 vector associated with transient immunological prophylactic treatment. The vector is designed to express itself in muscle tissue and the heart thanks to a Spc5-12 promoter sequence specific to these tissues. A total of 64 boys aged 6 to 10 with DMD who have retained their walking ability will be enrolled. * French ANSM as reporting member state for the EMA About Duchenne muscular dystrophy Duchenne muscular dystrophy is a rare progressive genetic disease that affects all the muscles in the body and mainly boys (1 in 5,000). It is caused by abnormalities in the gene responsible for the production of dystrophin, a structural protein essential for the stability of muscle fiber membranes and their metabolism. The absence of dystrophin leads to progressive degeneration of the skeletal and cardiac muscles, loss of walking and respiratory capacity, progressive heart failure, and death between the ages of 20 and 40. About Genethon A pioneer in the discovery and development of gene therapies for rare diseases, Genethon is a non-profit laboratory created by the AFM-Telethon. A first gene therapy drug, to which Genethon contributed, has been approved for marketing for spinal muscular atrophy. With more than 240 scientists and experts, Genethon's goal is to develop innovative therapies that change the lives of patients suffering from rare genetic diseases. Thirteen gene therapy products developed by Genethon or to which Genethon has contributed are currently undergoing clinical trials for diseases of the liver, blood, immune system, muscles, and eyes. Seven other products are in preparation for clinical trials over the next five years.

Rare 4000-years-old handprint reveals the forgotten potters of ancient Egypt
Rare 4000-years-old handprint reveals the forgotten potters of ancient Egypt

Business Insider

timea day ago

  • Business Insider

Rare 4000-years-old handprint reveals the forgotten potters of ancient Egypt

The recent discovery of a 4,000-year-old handprint on an artifact from ancient Egypt seems to have provided a remarkable window into the human touch that underlies one of the oldest civilizations in history. A 4,000-year-old handprint was discovered on an ancient Egyptian artifact named 'soul house.' The artifact was prepared for the Made in Ancient Egypt exhibition at the Fitzwilliam Museum. The handprint, dating back to the Middle Kingdom era (2055–1650 BC), marks a rare discovery. Researchers from the University of Cambridge discovered the handprint while getting artifacts ready for an exhibition. As a result, the findings would be displayed in the school's Made in Ancient Egypt expo at the inauguration of the Fitzwilliam Museum in October, as reported by the BBC. The handprint was discovered on a "soul house," which is a kind of clay model made to resemble a dwelling and left in graves as a sacrifice to the deceased. A complete, well-defined handprint can be seen beneath the base of the soul house, which dates to the Middle Kingdom era of Egypt, between 2055 and 1650 BC. "We've spotted traces of fingerprints left in wet varnish or on a coffin in the decoration, but it is rare and exciting to find a complete handprint underneath this soul house,' Ms Strudwick, senior egyptologist at the Fitzwilliam Museum, stated. "This was left by the maker who touched it before the clay dried. I have never seen such a complete handprint on an Egyptian object before," she added. The soul house was likely built using a wooden framework covered in clay to create a two-storey structure supported by pillars. The wooden core burnt away during the kiln-firing process, leaving behind voids. Loaves of bread, lettuce, and an ox's head are among the symbolic food offerings shown on the model's open front section. Although ancient Egyptian pottery was widely utilized and manufactured in large quantities, little is known about the craftspeople who created it. Potters were frequently of lesser social standing than goldsmiths or stonemasons.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store